Pa Julayi 5, Novo Nordisk adayambitsa gawo lachitatu la mayeso azachipatala a jekeseni wa CagriSema ku China, cholinga chake ndikufanizira chitetezo ndi mphamvu ya jekeseni ya CagriSema ndi semeglutide mu odwala onenepa komanso onenepa kwambiri ku China.
Jakisoni wa CagriSema ndi njira yophatikizira yayitali yomwe ikupangidwa ndi Novo Nordisk, zigawo zazikuluzikulu ndi GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide ndi amylin analog cagrilintide yanthawi yayitali.Jekeseni wa CagriSema utha kuperekedwa mosadukiza kamodzi pa sabata.
Cholinga chachikulu chinali kufanizitsa CagriSema (2.4 mg / 2.4 mg) ndi semeglutide kapena placebo kamodzi mlungu uliwonse subcutaneously.Novo Nordisk yalengeza zotsatira za kuyesa kwa CagriSema pochiza matenda a shuga a 2, zomwe zatsimikizira kuti zotsatira za hypoglycemic za CagriSema ndizabwinoko kuposa semeglutide, ndipo pafupifupi 90% ya ophunzira adakwaniritsa cholinga cha HbA1c.
Detayo inasonyeza kuti kuwonjezera pa zotsatira zazikulu za hypoglycemic, ponena za kuchepa kwa thupi, jekeseni ya CagriSema inaposa kwambiri semeglutide (5.1%) ndi cagrilintide (8.1%) ndi kuchepa kwa 15.6%.
Mankhwala opangidwa mwaluso a Tirzepatide ndiye woyamba padziko lonse lapansi kuvomerezedwa sabata iliyonse GIP/GLP-1 receptor agonist.Amaphatikiza zotsatira za ma incretins awiri kukhala molekyu imodzi yomwe imabayidwa kamodzi pa sabata ndipo ndi gulu latsopano lamankhwala amtundu wa 2 shuga.Tirzepatide idavomerezedwa ndi US Food and Drug Administration (FDA) mu Meyi 2022 kuti ipititse patsogolo kuwongolera kwa glycemic (pazakudya komanso masewera olimbitsa thupi) mwa akulu omwe ali ndi matenda a shuga a 2 ndipo pano amavomerezedwa ku European Union, Japan ndi mayiko ena.
Pa Julayi 5, Eli Lilly adalengeza za gawo lachitatu la kafukufuku wa SURPASS-CN-MONO pa kalembera wa mayeso azachipatala ndi njira yowulula zambiri zothandizira odwala amtundu wa 2.SURPASS-CN-MONO ndi kafukufuku wopangidwa mwachisawawa, wakhungu kawiri, woyendetsedwa ndi placebo wopangidwa kuti awunikire mphamvu ndi chitetezo cha tirzepatide monotherapy poyerekeza ndi placebo mwa anthu omwe ali ndi matenda a shuga a 2.Kafukufukuyu adakonza zophatikiza odwala 200 omwe ali ndi matenda a shuga amtundu wa 2 omwe sanagwiritse ntchito mankhwala oletsa shuga m'masiku 90 asanafike ulendo woyamba (kupatula muzochitika zina zachipatala, monga matenda oopsa, kugona m'chipatala, kapena opaleshoni yosankha, kwakanthawi kochepa (≤14). masiku) kugwiritsa ntchito insulin).
Matenda a shuga amtundu wa 2 akuyembekezeka kuvomerezedwa chaka chino
Mwezi watha, zotsatira za kafukufuku wa SURPASS-AP-Combo zidasindikizidwa Meyi 25 m'magazini ya blockbuster Nature Medicine.Zotsatira zake zidawonetsa kuti poyerekeza ndi insulin glargine, Tirzepatide idawonetsa HbA1c yabwinoko komanso kuchepetsa kulemera kwa anthu odwala matenda ashuga amtundu wa 2 m'chigawo cha Asia-Pacific (makamaka China): kuchepa kwa HbA1c mpaka 2.49% ndikuchepetsa thupi mpaka 7.2 kg. (9.4%) pa masabata a 40 a chithandizo, kusintha kwakukulu kwa lipids ya magazi ndi kuthamanga kwa magazi, komanso chitetezo chonse ndi kulekerera zinali zabwino.
Mayesero azachipatala a Phase 3 a SURPASS-AP-Combo ndi kafukufuku woyamba wa Tirzepatide wochitidwa makamaka mwa odwala aku China omwe ali ndi matenda a shuga a 2, motsogozedwa ndi Pulofesa Ji Linong wa ku Peking University People's Hospital.SURPASS-AP-Combo ikugwirizana ndi zotsatira za kafukufuku wapadziko lonse wa SURPASS, zomwe zimatsimikiziranso kuti matenda a shuga mwa odwala aku China amagwirizana ndi odwala padziko lonse lapansi, omwe ndi maziko a kafukufuku ndi chitukuko cha mankhwala atsopano. ku China komanso padziko lonse lapansi, komanso amapereka umboni wotsimikizika wotsimikizira kupatsa odwala aku China mwayi wogwiritsa ntchito mankhwala aposachedwa ochiza matenda a shuga komanso kugwiritsa ntchito kwawo kuchipatala ku China posachedwa.
Nthawi yotumiza: Sep-18-2023